Fig. 3From: Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIVPlasma viral load in rhesus macaque* receiving 125 mg/day aprepitant * eight male rhesus macaques (Macaca mulatta) were infected with SIVmac251. Treated animals (n = 4/group) were administered 125 mg of aprepitant daily by the oral route, starting at day 0 for the duration of the study. Results are presented as mean ± SD for each group of animalsBack to article page